Phase 3 Clinical Trials With Primary Completion Dates in January 2017
This is a list of Phase 3 trials with primary completion dates in January 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ALDR||Alder BioPharmaceuticals, Inc.||2017-01-01||Phase 3||NCT02559895||A Multicenter Assessment of ALD403 in Frequent Episodic Migraine|
|AMAG||AMAG Pharmaceuticals, Inc.||2017-01-01||Phase 3||NCT02937766||Study Assessing Injection Pain of MakenaÂ® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women|
|CMRX||Chimerix, Inc.||2017-01-01||Phase 3||NCT02439957||SURPASS: A Randomized, Double-Blind, Multicenter Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus (CMV) Disease in CMV Seropositive Kidney Transplant Recipients (BCV CMV vGCV)|
|IONS||Ionis Pharmaceuticals, Inc.||2017-01-01||Phase 3||NCT02658175||The Approach Extension Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome|
|MYGN||Myriad Genetics, Inc.||2017-01-01||Phase 3||NCT02000622||Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.|
|SGYP||Synergy Pharmaceuticals, Inc.||2017-01-01||Phase 3||NCT02706483||Long Term Safety Study of Plecanatide|
|SGYPU||Synergy Pharmaceuticals, Inc.||2017-01-01||Phase 3||NCT02706483||Long Term Safety Study of Plecanatide|